Anna Jirovec
Ottawa, ON, Canada
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Efficacy, effectiveness and immunogenicity of reduced HPV vaccination schedules: A review of available evidence.
Journal: Canada communicable disease report = Releve des maladies transmissibles au Canada
Published: July 18, 2024
Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, sensitizes cancer cells to VSVΔ51 oncolytic virotherapy.
Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: June 06, 2023
Vanadyl sulfate-enhanced oncolytic virus immunotherapy mediates the antitumor immune response by upregulating the secretion of pro-inflammatory cytokines and chemokines.
Journal: Frontiers in immunology
Published: August 30, 2022
Oncolytic virus driven T-cell-based combination immunotherapy platform for colorectal cancer.
Journal: Frontiers in immunology
Published: August 27, 2022
Identification of FDA-approved bifonazole as a SARS-CoV-2 blocking agent following a bioreporter drug screen.
Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: February 18, 2022
Immunotherapy for sarcomas: new frontiers and unveiled opportunities.
Journal: Journal for immunotherapy of cancer
Published: November 15, 2020
Oncolytic Rhabdovirus Vaccine Boosts Chimeric Anti-DEC205 Priming for Effective Cancer Immunotherapy.
Journal: Molecular therapy oncolytics
Published: January 15, 2020
The strategic combination of trastuzumab emtansine with oncolytic rhabdoviruses leads to therapeutic synergy.
Journal: Communications biology
Published: September 05, 2019
Transforming the prostatic tumor microenvironment with oncolytic virotherapy.
Journal: Oncoimmunology
Published: February 20, 2018
Showing 1-10 of 10
Last Updated: 09/26/2026